Navigation Links
Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Date:10/1/2007

eatment of cancer and inflammatory diseases, scheduled to enter Phase 1 clinical trials in the second half of 2007, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of initiating a Phase 1 study of RDEA119 in patients with advanced cancer and initiating clinical studies on three additional compounds this year, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... be hosting its sixth Medical Affairs ... 12:30PM (EDT) via a virtual roundtable to discuss ... Research." Best Practices, Medical Affairs Consortium ... sharing insights about the key challenges they face. ...
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... OAKS, Calif. , May 22, 2015 ... announced the Company has commenced termination of ... of brodalumab with AstraZeneca (LON:AZN, STO:AZN and ... IL-17 inhibitor, is in development for patients ... axial spondyloarthritis.  The decision was based on ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive ... the In-Vitro Diagnostics (IVD) market, announced today a further update regarding ... one of the largest manufacturers and distributors of magnetic beads for ... , ...
... Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, ... Manager Portal (the Portal), a free, easy-to-use online resource ... providers meet their daily client education and professional needs. The ... the 22nd National Conference on Social Work and HIV/AIDS, the ...
Cached Medicine Technology:CardioGenics Announces Update Regarding Status of Merck Agreement 2CardioGenics Announces Update Regarding Status of Merck Agreement 3Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 2Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 3Tibotec Therapeutics Debuts Innovative Web Portal for HIV/AIDS Front-Line Service Providers 4
(Date:5/22/2015)... (PRWEB) May 22, 2015 The American ... exciting events in June. They will hold a webinar ... and a two-day class on Classical Chinese Medicine. , ... 3, Dr. Steve Given, the Dean of Clinical Education, ... the new First Professional Doctorate program. ACTCM is currently ...
(Date:5/22/2015)... York, New York (PRWEB) May 22, 2015 ... http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals who ... due to its use continue to move forward ... Louisiana. According to a Pretrial Order dated May ... the preservation of documents and electronically stored information. ...
(Date:5/22/2015)... London, UK (PRWEB) May 22, 2015 ... the leading treatment option for chronic obstructive pulmonary ... UK’s GlaxoSmithKline plc and AstraZeneca plc as well ... for market share and position. But will market ... from the already well-entrenched products to completely new ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow ... LaSalle D. Leffall, on Monday, May 18, with an ... Rounds in the hospital’s Tower Auditorium. Leffall’s younger sister, ... trying to keep the secret. “I’d like to go ... he’ll know something is up,” she said. , After ...
(Date:5/22/2015)... LINCOLN, R.I. (PRWEB) May 22, 2015 Memorial ... so Amica Insurance is offering some tips to ... National Safety Council, there will be 383 traffic fatalities this ... tips from the National Highway Traffic Safety Association: , ... everyone in the vehicle is wearing a seatbelt, whether they’re ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2
... NEW YORK, April 28 PSI Corp. (Pink ... its partner in the,Digital Signage Network, has signed ... Network., David Foni, Chairman and CEO of ... and Texas are accretive to PSI,s network in,more ...
... Ala., April 28 HealthSouth Corporation,(NYSE: ... into a definitive agreement,through one of its ... of South Jersey, a 34-bed inpatient rehabilitation,hospital ... Partnership., "We are very pleased to ...
... found measurable gains in those with moderate to severe ... implanting specialized cells found in the human eye into ... were able to reduce symptoms and improve quality of ... The new treatment, dubbed Spheramine, reduced symptoms experienced when ...
... Ten outstanding geriatric social work faculty members have been ... Faculty Scholars Program , a venture funded by the ... The Gerontological Society of America , and directed by ... are provided with opportunities for professional development and $100,000 ...
... cord injuries is hampered by a reliance on animal ... new study in the upcoming edition of the peer-reviewed ... by scientists with the Physicians Committee for Responsible Medicine. ... dont have a drug to cure spinal cord injury ...
... The overall amputation rate in northern Illinois is declining ... disease, new research shows. , But not everyone ... from Northwestern University,s Feinberg School of Medicine has found ... West Side have a five times higher rate of ...
Cached Medicine News:Health News:PSI Corp. Announces Additional Hospitals and Medical Office Buildings to Utilize Its Digital Signage Network 2Health News:HealthSouth to Purchase The Rehabilitation Hospital of South Jersey 2Health News:HealthSouth to Purchase The Rehabilitation Hospital of South Jersey 3Health News:Eye Cell Implants Improve Parkinson's Symptoms 2Health News:Eye Cell Implants Improve Parkinson's Symptoms 3Health News:The Gerontological Society of america Announces 2008 Hartford Faculty Scholars 2Health News:Spinal cord injury research hampered by animal models, says new study 2Health News:African Americans have 5 times higher amputation rate 2
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
Medicine Products: